Cargando…

Molecular Genetics Overview of Primary Mitochondrial Myopathies

Mitochondrial disorders are the most common inherited conditions, characterized by defects in oxidative phosphorylation and caused by mutations in nuclear or mitochondrial genes. Due to its high energy request, skeletal muscle is typically involved. According to the International Workshop of Experts...

Descripción completa

Detalles Bibliográficos
Autores principales: Arena, Ignazio Giuseppe, Pugliese, Alessia, Volta, Sara, Toscano, Antonio, Musumeci, Olimpia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836969/
https://www.ncbi.nlm.nih.gov/pubmed/35160083
http://dx.doi.org/10.3390/jcm11030632
_version_ 1784649808352378880
author Arena, Ignazio Giuseppe
Pugliese, Alessia
Volta, Sara
Toscano, Antonio
Musumeci, Olimpia
author_facet Arena, Ignazio Giuseppe
Pugliese, Alessia
Volta, Sara
Toscano, Antonio
Musumeci, Olimpia
author_sort Arena, Ignazio Giuseppe
collection PubMed
description Mitochondrial disorders are the most common inherited conditions, characterized by defects in oxidative phosphorylation and caused by mutations in nuclear or mitochondrial genes. Due to its high energy request, skeletal muscle is typically involved. According to the International Workshop of Experts in Mitochondrial Diseases held in Rome in 2016, the term Primary Mitochondrial Myopathy (PMM) should refer to those mitochondrial disorders affecting principally, but not exclusively, the skeletal muscle. The clinical presentation may include general isolated myopathy with muscle weakness, exercise intolerance, chronic ophthalmoplegia/ophthalmoparesis (cPEO) and eyelids ptosis, or multisystem conditions where there is a coexistence with extramuscular signs and symptoms. In recent years, new therapeutic targets have been identified leading to the launch of some promising clinical trials that have mainly focused on treating muscle symptoms and that require populations with defined genotype. Advantages in next-generation sequencing techniques have substantially improved diagnosis. So far, an increasing number of mutations have been identified as responsible for mitochondrial disorders. In this review, we focused on the principal molecular genetic alterations in PMM. Accordingly, we carried out a comprehensive review of the literature and briefly discussed the possible approaches which could guide the clinician to a genetic diagnosis.
format Online
Article
Text
id pubmed-8836969
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88369692022-02-12 Molecular Genetics Overview of Primary Mitochondrial Myopathies Arena, Ignazio Giuseppe Pugliese, Alessia Volta, Sara Toscano, Antonio Musumeci, Olimpia J Clin Med Review Mitochondrial disorders are the most common inherited conditions, characterized by defects in oxidative phosphorylation and caused by mutations in nuclear or mitochondrial genes. Due to its high energy request, skeletal muscle is typically involved. According to the International Workshop of Experts in Mitochondrial Diseases held in Rome in 2016, the term Primary Mitochondrial Myopathy (PMM) should refer to those mitochondrial disorders affecting principally, but not exclusively, the skeletal muscle. The clinical presentation may include general isolated myopathy with muscle weakness, exercise intolerance, chronic ophthalmoplegia/ophthalmoparesis (cPEO) and eyelids ptosis, or multisystem conditions where there is a coexistence with extramuscular signs and symptoms. In recent years, new therapeutic targets have been identified leading to the launch of some promising clinical trials that have mainly focused on treating muscle symptoms and that require populations with defined genotype. Advantages in next-generation sequencing techniques have substantially improved diagnosis. So far, an increasing number of mutations have been identified as responsible for mitochondrial disorders. In this review, we focused on the principal molecular genetic alterations in PMM. Accordingly, we carried out a comprehensive review of the literature and briefly discussed the possible approaches which could guide the clinician to a genetic diagnosis. MDPI 2022-01-26 /pmc/articles/PMC8836969/ /pubmed/35160083 http://dx.doi.org/10.3390/jcm11030632 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Arena, Ignazio Giuseppe
Pugliese, Alessia
Volta, Sara
Toscano, Antonio
Musumeci, Olimpia
Molecular Genetics Overview of Primary Mitochondrial Myopathies
title Molecular Genetics Overview of Primary Mitochondrial Myopathies
title_full Molecular Genetics Overview of Primary Mitochondrial Myopathies
title_fullStr Molecular Genetics Overview of Primary Mitochondrial Myopathies
title_full_unstemmed Molecular Genetics Overview of Primary Mitochondrial Myopathies
title_short Molecular Genetics Overview of Primary Mitochondrial Myopathies
title_sort molecular genetics overview of primary mitochondrial myopathies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836969/
https://www.ncbi.nlm.nih.gov/pubmed/35160083
http://dx.doi.org/10.3390/jcm11030632
work_keys_str_mv AT arenaignaziogiuseppe moleculargeneticsoverviewofprimarymitochondrialmyopathies
AT pugliesealessia moleculargeneticsoverviewofprimarymitochondrialmyopathies
AT voltasara moleculargeneticsoverviewofprimarymitochondrialmyopathies
AT toscanoantonio moleculargeneticsoverviewofprimarymitochondrialmyopathies
AT musumeciolimpia moleculargeneticsoverviewofprimarymitochondrialmyopathies